ALKS
HealthcareAlkermes plc
$28.00
$-0.26 (-0.92%)
Jan 5, 2026
Price History (1Y)
Analysis
Alkermes plc is a healthcare company operating in the specialty and generic drug manufacturers sector. The company has a significant scale, with a market capitalization of $4.62 billion, annual revenue of $1.52 billion, and approximately 1800 employees. The company's financial health appears to be robust, with gross margin at 86.0%, operating margin at 22.6%, and profit margin at 22.3%. Return on equity (ROE) stands at 22.3% and return on assets (ROA) is 10.0%. The balance sheet shows $71.60 million in debt, which represents a relatively low level of indebtedness, while cash reserves total $1.11 billion. Valuation metrics indicate a price-to-earnings ratio (TTM) of 14.07 and forward P/E of 12.96. Revenue growth has been steady at 4.2% year-over-year, but earnings growth has been negative at -12.1%. The company does not pay dividends, with a payout ratio of 0.0%.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Alkermes plc
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Visit website →Key Statistics
- Market Cap
- $4.62B
- P/E Ratio
- 14.07
- 52-Week High
- $36.45
- 52-Week Low
- $25.17
- Avg Volume
- 2.27M
- Beta
- 0.43
Company Info
- Exchange
- NMS
- Country
- Ireland
- Employees
- 1,800